AGENDA AT GLANCE
AGENDA AT GLANCE
Day 2
26th September 2025
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
👤 Devi B. Basnet, Senior Research Scientist, Medytox, South Korea
👤 Wei-Han Lee, Director CMC, OBI Pharma, Taiwan
Leadership Panel Discussion: The Evolving Landscape of Antibody-Drug Conjugates (ADCs) in Oncology and Beyond
Premier Ballroom A
9:00
Leadership Panel Discussion: Redefining the Future — Innovation and Real-World Readiness of Next-Generation ADCs
- Discussing the momentum behind next-generation ADCs and the practical challenges of translating innovative designs.
- Examining the potential of ADCs beyond oncology and what it takes to translate innovation into new therapeutic areas.
- How are ADC innovators evolving to accelerate and support the next wave of ADC breakthroughs?
Moderator:
👤 Peng Guo, Principal Investigator, Hangzhou Institute of Medicine, Chinese Academy of Sciences, China
Panelists:
👤 Doo Young Jung, Chief Executive Officer, PinotBio, South Korea
👤 Bryan Yeung, Vice President Chemistry, Axcynsis Therapeutics, Singapore
👤 Tae Kyo Park, Chief Executive Officer, Intocell, South Korea
Automation and Bioprocessing 4.0: The Future of Biomanufacturing
Premier Ballroom A
9:50
Advances in AI-Assisted Pharma Manufacturing with MasterControl Manufacturing Excellence
- A glimpse into the future of Pharma Manufacturing and the ability of 'Assistive Intelligence' to help mitigate risk, prevent deviations and improve efficiency.
- Explore how AI-driven insights, predictive analytics, and real-time process optimization are reshaping pharmaceutical operations.
- Learn how MasterControl Manufacturing Excellence integrates AI to elevate quality outcomes, streamline batch records, and enable proactive decision-making on the shop floor.
- Whether you're modernizing legacy systems or aiming for a true Pharma 4.0 transformation, this session offers practical strategies and real-world examples to help accelerate your digital maturity.
👤 Sue Marchant, Chief Product Officer, MasterControl, United States
Optimizing ADC Target Selection and Engineering for Maximum Efficacy
Premier Ballroom A
10:05
Enhancing the Precision and Efficacy of ADCs: Development of BsADCs
- MOA and Landscape of BsADCs
- Enhancing the Precision and Efficacy by Innovative BsADCs
- Overcoming the CMC Challenges in BsADC Development
👤 Min Zhao, Vice President CMC, Innolake Biopharma, China
10:30
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Exhibition Hall, Ballroom B
Scaling Up ADC Production: Overcoming Challenges in Bioconjugation and Purification
Premier Ballroom C
11:15
All Roads Lead to Rome: Exploring New Mechanisms of Action for ADCs
- Novel Mechanism: Established a caspase-1-independent pyroptosis pathway via lysosomal cathepsin S, expanding ADC mechanisms beyond apoptosis.
- Innovative Payload: Developed a near infrared light (NIR)-activatable ADC using antibody–photosensitizer conjugates for tumoral pyroptosis induction.
- Synergistic Strategy: Combined NIR-triggered pyroptosis with PD-1 blockade to enhance antitumor immunity and prevent tumor recurrence.
👤 Peng Guo, Principal Investigator, Hangzhou Institute of Medicine, National Academy of Sciences, China
11:40
Development of Novel ADC Targeting Neurotensin receptor-1 (NTSR1) for Head and Neck Cancer Therapy
- Identify NTSR1 as a novel therapeutic target at unmet medical indications: R/M HNSCC and mCRPC
- DCBAD2301 shows high productivity and good stability.
- DCBAAD demonstrates low immunogenicity, favorable pharmacokinetics, excellent efficacy and good safety profile.
👤 Chun-Mien Chang, Senior Scientist, Development Centre for Biotechnology, Taiwan
12:05
OBI Pharma: Driving ADC Excellence with OBI ADC Enabling Technologies
- Advancing ADC Conjugation: a Refined Glycan-Based, One-Pot, Plug-n-play Platform
- Innovative Linker Design for Optimized Stability and Enhance Therapeutic Profile
- Unlocking Extensive Flexibility: Versatile DARs and Dual-Payload Capabilities
👤 Wei Han Lee, Senior Director CMC, OBI Pharma, Taiwan
12:30
Lunch Break, Exhibition Viewing & 1-1 Attendee Networking
Advancing Payloads and Linker Technologies for Next-Generation ADCs
Premier Ballroom A
2:00
Discovery and Development of Novel Top1i Payload ADC Platform, Pinot-ADC and Its Applications
- Discovery of Novel Top1i Payload, PBX-7016
- Applications of PBX-7016 in various clinical and preclinical ADC candidates
- Innovative hydrophilic, tandem cleavage linker for improved safety profile of ADCs
- Novel antibody platform to enable DAR 1 conjugates and dual payload conjugates with various DAR.
👤 Doo-Young Jung, Chief Executive Officer, PinotBio, South Korea
2:25
Preclinical Development of AT2604, an ALPP/ALPPL2 Targeting Antibody Drug Conjugate
- Potential first-in-class ADC program targeting alkaline phosphatase ALPP/ALPPL2
- Strong binding to ALPP/ALPP2; selective against other alkaline phosphatase (AP) family members
- In vivo efficacy demonstrated in multiple CDX and PDX tumor models
👤 Bryan Yeung, Vice President Chemistry, Axcynsis Therapeutics, Singapore
2:50
Applications of OHPAS and PMT in ADC Systems
- Structural Overview of OHPAS and Mechanisms of Payload Release
- Mechanistic Insights into PMT
- Development of Novel Camptothecin-Based Payloads
👤 Tae-Kyo Park, Chief Executive Officer, Intocell, South Korea
3:15
TEC Targeting ADC with Highly Potent Bystander Effect
- Tumor endothelial cells and tumor cells targeting
- Bystander effect by using the dual enzymes (caspase-3/7, cathepsin B) sensitive peptide linker
- Potent ADC for the treatment of hyper-vascular tumors
👤 Young-Ro Byun, Founder, Pharosgen Co., Professor, Seoul National University, South Korea
3:40
Chairman Closing Remarks
👤 Devi B. Basnet, Senior Research Scientist, Medytox, South Korea
👤 Wei Han Lee, Director CMC, OBI Pharma, Taiwan
3:50
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Premier Ballroom A
4:30
End of Conference Day
For Speaking Opportunities, Kindly Contact:
Umairoh Nurul Hafifa
Conference Producer
e: [email protected] | p: +62 856 0028 7725
Share With Your Network
